Total Assets
Stockholders' Equity
Cash & Equivalents
Long-Term Debt
Revenue trend
Balance Sheet
Income Statement
Per Share & Cash Flow
Insider activity
SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Aug 29, 2026
as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗
In its FY2026 report, Xilio Therapeutics, Inc. reported total assets of $154.3M, stockholders' equity of $72.3M, and revenue of $18.7M. Every figure below is taken directly from Xilio Therapeutics, Inc.'s SEC filings: each links to the source document on EDGAR.
as of Jun 30, 2026 · 10-Q
10-Q (quarterly) · period ended Jun 30, 2026
10-Q (quarterly) · period ended Jun 30, 2026
| EPS (diluted) | $-0.33 | Earnings | source ↗ |
| EPS (basic) | $-0.33 | Earnings | source ↗ |
| Shares Outstanding | 6.6M | Common | source ↗ |
| Cash from Operations | -$18.8M | Net | source ↗ |
| Cash from Financing | $4.5M | Net | source ↗ |
| Cash from Investing | -$19,000 | Net | source ↗ |
Form 4 open-market activity, last 180 days
No material restatements detected across 137annual fact-keys: this company's as-filed numbers have held between filings. Point-in-time and as-of history are available via the API.
As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail behind the counts above, plus MCP access for your own agents, across the whole SEC universe.
Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.